NinePointTwo Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

NinePointTwo Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$329K	Buy	+37,496	New	+$307K	0.13%	98
2023 Q3	–	Sell	-8,444	Closed	-$213K	–	335
2023 Q2	$213K	Buy	+8,444	New	+$263K	0.08%	196
2023 Q1	–	Sell	-11,774	Closed	-$217K	–	314
2022 Q4	$217K	Buy	+11,774	New	+$269K	0.09%	95

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NinePointTwo Capital's RVNC Position: Q4 2023 in Review

NinePointTwo Capital opened a new position in Revance Therapeutics, Inc. (RVNC) in Q4 2023: 37,496 shares worth $329K. The stake represents 0.13% of the portfolio and ranks #98 among its holdings. This is a return to the name: NinePointTwo Capital previously reported a position in RVNC as recently as Q2 2023.

NinePointTwo Capital first reported a position in RVNC in Q4 2022 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

NinePointTwo Capital held 37,496 shares of Revance Therapeutics, Inc. worth $329K as of Q4 2023.
Revance Therapeutics, Inc. was a new NinePointTwo Capital position in Q4 2023.
Revance Therapeutics, Inc. made up 0.13% of NinePointTwo Capital's portfolio in Q4 2023, its #98 holding.
NinePointTwo Capital first reported a position in Revance Therapeutics, Inc. in Q4 2022 and has held it in 3 quarters since.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.